Conditions: Breast Neoplasms
Allocation: NON_RANDOMIZED | Intervention model: 
Enrollment: 28
Healthy volunteers: no

Brief summary:
Progression-free rate after 16 weeks of BIBW 2992 administration in association with letrozole

Detailed description:

Arms:
arm 1: To study BIBW 2992 in association with letrozole in hormonoresistant metastatic breast cancer arm 2: Hormonotherapy for metastatic breast cancer

Interventions: intervention 1: BIBW 2992 intervention 2: BIBW 2992 intervention 3: Letrozole intervention 4: Letrozole
Intervention descriptions: intervention 1: BIBW 2992 at high and medium dosages intervention 2: BIBW 2992 at high and medium dosages intervention 3: Letrozole at standard dosage intervention 4: Letrozole at standard dosage

Protocol document: